Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Nivolumab plus low-dose Ipilimumab in first-line MSI-H advanced gastric or esophagogastric junction cancer
jRCT2080225304Phase 2Completed
- Sponsor
- Hisato Kawakami (Coordinating Investigator)
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Hisato Kawakami (Coordinating Investigator). Primary endpoint: Objective response rate (ORR). Started Aug 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080225304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225304.